Table 4 Agreement between the panelists and the SBM affiliated breast surgeons for the questions related to systemic treatment
Questions | Panelists before brainstorming | Affiliated breast surgeons | ||
|---|---|---|---|---|
Disagreement n (%) | Agreement n (%) | Disagreement n (%) | Agreement n (%) | |
Q35. In patients with no BRCA germline mutation, platinum agents should be recommended in neoadjuvant treatment. | 11 (40.7) | 16 (59.3) | 105 (49.1) | 109 (50.9) |
Q36. In patients with the BRCA germline mutation, the use of platinum agents in neoadjuvant treatment should be recommended. | 11 (40.7) | 16 (59.3) | 39 (18.2) | 175 (81.8) |
Q37. In patients who will be submitted to neoadjuvant treatment, the addition of immunotherapy should be recommended as routine. | 13 (48.1) | 14 (51.9) | 149 (69.6) | 65 (30.4) |
Q38. In patients who will be submitted to neoadjuvant treatment, PD-L1 status should be taken into consideration when recommending immunotherapy. | 14 (51.9) | 13 (48.1) | 63 (29.4) | 151 (70.6) |
Q39. BRCA status should play a role in the decision regarding whether to recommend neoadjuvant treatment with immunotherapy. | 22 (81.5) | 5 (18.5) | 120 (56.1) | 94 (43.9) |
Q40. In patients who will be submitted to neoadjuvant treatment with immunotherapy, dose-dense anthracycline-based chemotherapy should be used. | 7 (25.9) | 20 (74.1) | 53 (24.8) | 161 (75.2) |
Q41. In patients with no BRCA germline mutation submitted to neoadjuvant treatment with immunotherapy and who achieve pCR, immunotherapy should be continued during adjuvant therapy. | 11 (40.7) | 16 (59.3) | 116 (54.2) | 98 (45.8) |
Q42. In patients with no BRCA germline mutation submitted to neoadjuvant treatment with immunotherapy and who have residual disease, immunotherapy should be continued during adjuvant therapy. | 7 (25.9) | 20 (74.1) | 62 (29.0) | 152 (71.0) |
Q43. In patients with no BRCA germline mutation submitted to neoadjuvant therapy with immunotherapy and in whom there is residual disease, the use of adjuvant immunotherapy associated with capecitabine should be suggested. | 13 (48.1) | 14 (51.9) | 54 (25.2) | 160 (74.8) |
Q44. In patients with the BRCA germline mutation submitted to neoadjuvant therapy with immunotherapy and who achieve pCR, the use of adjuvant immunotherapy associated with olaparib should be suggested. | 18 (66.7) | 9 (33.3) | 104 (48.6) | 110 (51.4) |